Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bandwidth Inc (BAND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bandwidth Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $284.5 (market cap $39.89B), while Bandwidth Inc trades at $73.41 (market cap $2.42B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.5× Bandwidth Inc's market cap, and Bandwidth Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BAND | |
|---|---|---|
Market Cap | $39.89B | $2.42B |
Sector | Health | Technology |
52-Week High | $491.22 | $78.44 |
52-Week Low | $278.09 | $12.82 |
Enterprise Value | $38.15B | $2.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Bandwidth (BAND) trades at $75.48, down 3.77% on the day, with strong technical momentum despite recent weakness. The stock shows bullish technical signals with 19 buy indicators versus 6 sell, while fundamentals reveal mixed performance with negative net income margins (-0.64%) but solid revenue growth to $753.82 million in 2025. Recent news highlights AI platform expansion and a $275 million convertible notes offering to fuel growth initiatives.
Outlook remains cautiously optimistic with 75% analyst buy ratings and an $85 high price target, though profitability challenges and elevated valuation metrics (EV/EBITDA 63.18) present risks. The upcoming Q2 2026 earnings report on July 29 will be crucial for validating the AI-driven growth narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →
